Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 22Immunoglobulin Light-chain Amyloidosis 4Waldenstrom Macroglobulinemia 3Recurrence 2Lymphoma, T-Cell, Peripheral 2Smoldering Multiple Myeloma 1Sarcoma, Kaposi 1Proteostasis Deficiencies 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm, Residual 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Amyloidosis 1

Interventions

Rituximab 45Cyclophosphamide 38ibrutinib 22fludarabine 22acalabrutinib 21venetoclax 20zanubrutinib 17Lenalidomide 17Bendamustine Hydrochloride 17obinutuzumab 16fludarabine phosphate 14Magnetic Resonance Spectroscopy 14Cytarabine 14Specimen Handling 13CT-P10 13pirtobrutinib 12Biopsy 12glofitamab 10Etoposide 10Whole-Body Irradiation 9Vincristine 7Peripheral Blood Stem Cell Transplantation 7Mycophenolic Acid 7Melphalan 7Doxorubicin 7brexucabtagene autoleucel 6Cyclosporine 6orelabrutinib 5Methotrexate 5Immunotherapy, Adoptive 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Mantle-Cell × ixazomib × 1 year × Clear all
NCT02339922 2026-03-05

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

University of Washington

Phase 2 Active not recruiting
33 enrolled 16 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡